Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Therapeutic Role of Concomitant Intranasal Antihistamine and Corticosteroid in Patient With Perennial Allergic Rhinitis Whose Symptoms Are Not Controlled With Intranasal Corticosteroid

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05708157

Acronym

INCS/INAH

Enrollment

240

Registered

2023-02-01

Start date

2023-01-17

Completion date

2024-02-29

Last updated

2023-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Brief summary

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale \[VAS\] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Detailed description

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale \[VAS\] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid. In addition to VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be measured before treatment (baseline) and 2 week after treatment. The differences between parameters before treatment and those after 2-week treatment will be statistically analyzed using paired student t test, and p\<0.05 was considered statistically significant.

Interventions

DRUGconcomitant intranasal antihistamine and corticosteroid

concomitant intranasal administration with antihistamine and corticosteroid

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Perinnial allergic rhinitis diagnosed by a doctor * Positive for one or more of inhalant perinneal allergen in skin prick test or serum specific IgE measurement * Age: 19 years or older * Allergic rhinitis symptoms not controlled (VAS ≥5) by 2-week treatment with intranasal corticosteroid

Exclusion criteria

* Compliance for one or more drugs in last 2 weeks: \<80% * Use of oral corticosteroid, oral or intranasal decongestant in last 2 weeks * Initiation of allergen-specific immunotherapy in last 12 months * Seasonal allergic rhinitis * Chronic rhinosinusitis other than allergic rhinitis * Nasal polyposis * Comorbid diseases including infectious, respiratory, cardiologic, renal, gastrointestinal, endocrinologic, oncologic, hemotologic and immunologic disorders which investigators judge to affect on the study significantly. * Patients' rejection * Pregenancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
TNSS	2 week	total nasal symptom score

Secondary

Measure	Time frame	Description
RQLQ	2 week	rhinoconjunctivitis quality-of-life questionnares
VAS	2 week	visual analogue scale
TOSS	2 week	total nasal symptom score

Countries

South Korea

Contacts

Primary ContactSang Min Lee, MD, PhD

sangminlee77@naver.com82324582713

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026